Non-transplant-related treatment options in follicular lymphoma

Biology of Blood and Marrow Transplantation

Volumn 12, Issue SUPPL. 1, 2006, Pages 53-58

  Freedman, Arnold S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Follicular lymphoma

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; CANCER VACCINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GALIXIMAB; IBRITUMOMAB TIUXETAN; INTERLEUKIN 12; INTERLEUKIN 2; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PURINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; RADIOIMMUNOTHERAPY; TREATMENT FAILURE; VACCINATION; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; LYMPHOMA, FOLLICULAR; NEOPLASM STAGING;

EID: 29844445603     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.10.003     Document Type: Article

References (37)

1. P. Solal-Celigny P. Roy P. Colombat et al. Follicular lymphoma international prognostic index Blood 104 2004 1258-1265
2. M.P. Mac Manus R.T. Hoppe Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University J Clin Oncol. 14 1996 1282-1290
3. S.M. Kelsey A.C. Newland G.V. Hudson A.M. Jelliffe A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma Med Oncol. 11 1994 19-25
4. K.M. Ardeshna P. Smith A. Norton et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial Lancet 362 2003 516-522
5. P.W. Johnson A.Z. Rohatiner J.S. Whelan et al. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center J Clin Oncol. 13 1995 140-147
6. B.A. Peterson G.R. Petroni G. Frizzera et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the cancer and leukemia group B J Clin Oncol. 21 2003 5-15
7. P. McLaughlin L.M. Fuller W.S. Velasquez et al. Stage III follicular lymphoma: Durable remissions with a combined chemotherapy-radiotherapy regimen J Clin Oncol. 5 1987 867-874
8. P. Solal-Celigny P. Brice N. Brousse et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol. 14 1996 514-519
9. A. Hagenbeek H. Eghbali S. Monfardini et al. Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Final analysis of a prospective randomized phase III intergroup trial of 381 patients [abstract] Blood 98 2001 843a
10. I.W. Flinn J.C. Byrd C. Morrison et al.Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies Blood 96 2000 71-75
11. W.S. Velasquez D. Lew T.M. Grogan et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma S9501 J Clin Oncol. 21 2003 1996-2003
12. J.D. Hainsworth H.A. Burris III L.H. Morrissey et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma Blood 95 2000 3052-3056
13. P. Colombat G. Salles N. Brousse et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation Blood 97 2001 101-106
14. J.D. Hainsworth S. Litchy H.A. Burris III et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma J Clin Oncol. 20 2002 4261-4267
15. T.E. Witzig A.M. Vukov T.M. Habermann et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group J Clin Oncol. 23 2005 1103-1108
16. M. Ghielmini S.F. Schmitz S.B. Cogliatti et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule Blood 103 2004 4416-4423
17. M.S. Czuczman R. Weaver B. Alkuzweny J. Berlfein A.J. Grillo-Lopez Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up J Clin Oncol. 22 2004 4711-4716
18. D. Maloney O. Press R. Braziel et al. A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800 [abstract] Blood 98 2001 843a
19. M.S. Czuczman A. Koryzna A. Mohr et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma J Clin Oncol. 23 2005 694-704
20. R. Marcus K. Imrie A. Belch et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma Blood 105 2005 1417-1423
21. 131I-tositumomab therapy as initial treatment for follicular lymphoma N Engl J Med. 352 2005 441-449
22. O.W. Press J.M. Unger R.M. Braziel et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 Blood 102 2003 1606-1612
23. P. Solal-Celigny E. Lepage N. Brousse et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial J Clin Oncol. 16 1998 2332-2338
24. R.I. Fisher B.W. Dana M. LeBlanc et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809 J Clin Oncol. 18 2000 2010-2016
25. R.J. Klasa R.M. Meyer C. Shustik et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen J Clin Oncol. 20 2002 4649-4654
26. P. McLaughlin A.J. Grillo-Lopez B.K. Link et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol. 16 1998 2825-2833
27. T.A. Davis A.J. Grillo-Lopez C.A. White et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment J Clin Oncol. 18 2000 3135-3143
28. R. Forstpointner M. Dreyling R. Repp et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 104 2004 3064-3071
29. T.E. Witzig L.I. Gordon F. Cabanillas et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol. 20 2002 2453-2463
30. M.S. Kaminski J. Estes K.R. Zasadny et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience Blood 96 2000 1259-1266
31. T.A. Davis M.S. Kaminski J.P. Leonard et al. The radioisotope contributes significantly to the activity of radioimmunotherapy Clin Cancer Res. 10 2004 7792-7798
32. J.M. Bennett M.S. Kaminski J.P. Leonard et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab Blood 105 2005 4576-4582
33. J.W. Friedberg D. Neuberg J.G. Gribben et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma Br J Haematol. 117 2002 828-834
34. J.P. Leonard M. Coleman J. Ketas et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma J Clin Oncol. 23 2005 5044-5051
35. M.S. Czuczman A. Thall T.E. Witzig et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma J Clin Oncol. 23 2005 4390-4398
36. J.S. Waters A. Webb D. Cunningham et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma J Clin Oncol. 18 2000 1812-1823
37. F.J. Hsu C.B. Caspar D. Czerwinski et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial Blood 89 1997 3129-3135